OptiScan Biomedical Inc.

OptiScan Biomedical's OptiScanner 5000 bedside blood monitoring system automates monitoring of patients' plasma glucose levels in the intensive care unit, and the company is expanding its platform to measure hemoglobin and central venous oxygen saturation levels. Monitoring these metrics can provide early warning when a critically ill patient's condition goes downhill. The OptiScanner 5000 has been sold in Europe since 2014. OptiScan Biomedical nabbed $29.5 million in venture capital funding last quarter. 

Continue >>

[image courtesy of the company]